Company news
Diamedica Therapeutics Inc. (NASDAQ:DMAC) news
Every Diamedica Therapeutics Inc. press release and news update in one place — announcements, filings coverage, and company updates for investors.
Press releases & updates
DiaMedica Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Highlights
August 10, 2026
DiaMedica Therapeutics to Report Second Quarter 2026 Financial Results and Provide a Business Update August 11, 2026
August 4, 2026
DiaMedica Therapeutics Announces First Patients Dosed in Phase 2 Trial of DM199 for the Treatment of Fetal Growth Restriction
June 23, 2026
DiaMedica Receives FDA Feedback on DM199 Preeclampsia Nonclinical Program
June 16, 2026
DiaMedica Therapeutics to Present at the Jefferies Global Healthcare Conference 2026
May 27, 2026
DiaMedica Therapeutics Announces 75% Enrollment Milestone in ReMEDy2 Phase 2/3 Acute Ischemic Stroke Trial
May 20, 2026
DiaMedica Therapeutics to Participate in the 2026 RBC Capital Markets Global Healthcare Conference
May 12, 2026
DiaMedica Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Highlights
May 6, 2026
DiaMedica Therapeutics to Report First Quarter 2026 Financial Results and Provide a Business Update May 7, 2026
April 30, 2026
DiaMedica Therapeutics Reports Full Year 2025 Financial Results and Provides Business Highlights
March 30, 2026
DiaMedica Therapeutics to Report Fourth Quarter 2025 Financial Results and Provide a Business Update March 31, 2026
March 23, 2026
DiaMedica Therapeutics Receives Health Canada Clearance to Initiate Phase 2 Study of DM199 in Preeclampsia
March 5, 2026
DiaMedica Therapeutics to Participate in Upcoming March Investor Conferences
February 24, 2026
DiaMedica Announces Inducement Grants Under Nasdaq Listing Rule 5635(4)
January 19, 2026
DiaMedica Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
January 16, 2026
DiaMedica Therapeutics Provides DM199 Preeclampsia Program Update Following Pre-IND Meeting with FDA
December 18, 2025
DiaMedica Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Highlights
November 12, 2025
DiaMedica Therapeutics to Participate in the Jefferies Global Healthcare Conference in London
November 10, 2025
DiaMedica Therapeutics to Report Third Quarter 2025 Financial Results and Provide a Business Update November 13, 2025
November 6, 2025
DiaMedica Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
September 29, 2025
DiaMedica Therapeutics to Participate in Upcoming Investor Conferences
September 5, 2025
DiaMedica Therapeutics to Participate in Cantor Global Healthcare Conference
September 2, 2025
DiaMedica Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Highlights
August 12, 2025
DiaMedica Therapeutics Appoints Julie Krop, MD, as Chief Medical Officer
August 6, 2025
DiaMedica Therapeutics to Report Second Quarter 2025 Financial Results and Provide a Business Update August 13, 2025
August 5, 2025
DiaMedica Therapeutics Announces Closing of $30.1 Million Private Placement
July 23, 2025
DiaMedica Therapeutics Raises $30 Million in Private Placement to Accelerate Industry Leading Preeclampsia and Fetal Growth Restriction P...
July 21, 2025
DiaMedica Therapeutics Reports Positive Interim Phase 2 Preeclampsia Results: Statistically Significant Reductions in Blood Pressure and ...
July 17, 2025
DiaMedica Therapeutics Announces Inclusion in the Russell 2000® and Russell 3000® Indexes
June 24, 2025
DiaMedica Therapeutics to Present at Jefferies Global Healthcare Conference 2025
May 22, 2025
DiaMedica Therapeutics Announces Key Opinion Leader Webinar on DM199 (Rinvecalinase Alfa) for the Treatment of Preeclampsia
May 19, 2025
DiaMedica Therapeutics Announces Poster Presentation at European Stroke Organisation Conference – ESOC 2025
May 14, 2025
DiaMedica Therapeutics Reports First Quarter 2025 Financial Results And Provides Business Highlights
May 13, 2025
DiaMedica Therapeutics to Participate in Upcoming Investor Conferences in May
May 8, 2025
DiaMedica Therapeutics to Report First Quarter 2025 Financial Results and Provide a Business Update May 14, 2025
May 7, 2025
DiaMedica Therapeutics Provides a Business Update and Announces Full Year 2024 Financial Results
March 17, 2025
DiaMedica Therapeutics to Report Fourth Quarter 2024 Financial Results and Provide a Business Update March 18, 2025
March 11, 2025
DiaMedica Therapeutics Appoints Daniel J. O’Connor to the Board of Directors
February 24, 2025
DiaMedica Therapeutics Announces Publication of DM199’s Mechanism of Action for the Treatment of Acute Ischemic Stroke (AIS) in the Journ...
February 20, 2025
DiaMedica Therapeutics to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference
February 10, 2025
DiaMedica Therapeutics Announces Formation of Scientific Advisor Board to Support the Development of DM199 for the Treatment of Preeclampsia
December 3, 2024
DiaMedica Therapeutics Announces Dosing of First Patient in Phase 2 Trial of DM199 in the Treatment of Preeclampsia
November 13, 2024
DiaMedica Therapeutics Provides a Business Update and Announces Third Quarter 2024 Financial Results
November 13, 2024
DiaMedica Therapeutics to Participate in Upcoming Craig-Hallum 15th Annual Alpha Select Conference
November 12, 2024
DiaMedica Therapeutics to Provide a Business Update and Report Third Quarter 2024 Financial Results November 14, 2024
November 6, 2024
DiaMedica Therapeutics Announces Regulatory Approval to Begin Phase 2 Trial of DM199 in the Treatment of Preeclampsia
October 9, 2024
DiaMedica Therapeutics Upcoming Conference Participation
September 4, 2024
DiaMedica Therapeutics Provides a Business Update and Announces Second Quarter 2024 Financial Results
August 7, 2024
DiaMedica Therapeutics to Provide a Business Update and Report Second Quarter 2024 Financial Results August 8, 2024
August 1, 2024
DiaMedica Therapeutics Releases Preeclampsia White Paper and Announces Key Opinion Leader Webinar on DM199 (Rinvecalinase Alfa) for the T...
July 11, 2024